Targeting the ERBB family in cancer: couples therapy (Q38129286)

29 August 2017

Targeting the ERBB family in cancer: couples therapy (English)

1 reference

29 August 2017

Mikkel W Pedersen

2

0 references

Terrance G Johns

object named as

Terrance G Johns

series ordinal

3

0 references

author name string

Niall Tebbutt

series ordinal

1

1 reference

PubMed ID

23949426

29 August 2017

language of work or name

English

0 references

publication date

16 August 2013

1 reference

29 August 2017

Nature Reviews Cancer

1 reference

29 August 2017

13

1 reference

29 August 2017

663-673

1 reference

29 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc3559

29 August 2017

0 references

cites work

Role of HER receptors family in development and differentiation.

1 reference

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

31 March 2020

1 reference

The ErbB/HER receptor protein-tyrosine kinases and cancer

31 March 2020

1 reference

The ErbB receptor tyrosine family as signal integrators

31 March 2020

1 reference

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

31 March 2020

1 reference

Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling

31 March 2020

1 reference

The ERBB network: at last, cancer therapy meets systems biology.

31 March 2020

1 reference

ErbB receptors and signaling pathways in cancer

31 March 2020

1 reference

Role of ErbB4 in breast cancer

31 March 2020

1 reference

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

31 March 2020

1 reference

Small molecules with EGFR-TK inhibitor activity

31 March 2020

1 reference

Epidermal growth factor receptor targeting in cancer

31 March 2020

1 reference

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

31 March 2020

1 reference

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

31 March 2020

1 reference

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

31 March 2020

1 reference

Interaction of antibodies with ErbB receptor extracellular regions

31 March 2020

1 reference

Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

31 March 2020

1 reference

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

31 March 2020

1 reference

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

31 March 2020

1 reference

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

31 March 2020

1 reference

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

31 March 2020

1 reference

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents

31 March 2020

1 reference

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

31 March 2020

1 reference

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts

31 March 2020

1 reference

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

31 March 2020

1 reference

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

31 March 2020

1 reference

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models

31 March 2020

1 reference

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

31 March 2020

1 reference

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

31 March 2020

1 reference

ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor

31 March 2020

1 reference

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation

31 March 2020

1 reference

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

31 March 2020

1 reference

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function

31 March 2020

1 reference

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

31 March 2020

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

31 March 2020

1 reference

31 March 2020

1 reference

Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer

31 March 2020

1 reference

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

31 March 2020

1 reference

Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.

31 March 2020

1 reference

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization

31 March 2020

1 reference

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

31 March 2020

1 reference

EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.

31 March 2020

1 reference

Survival of cancer cells is maintained by EGFR independent of its kinase activity

31 March 2020

1 reference

Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin

31 March 2020

1 reference

Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

31 March 2020

1 reference

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

31 March 2020

1 reference

Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial

31 March 2020

1 reference

The EGFRvIII variant in glioblastoma multiforme

31 March 2020

1 reference

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

31 March 2020

1 reference

Nuclear EGFR contributes to acquired resistance to cetuximab

31 March 2020

1 reference

Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells

31 March 2020

1 reference

Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism

31 March 2020

1 reference

Epidermal growth factor receptor translocation to the mitochondria: regulation and effect

31 March 2020

1 reference

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study

31 March 2020

1 reference

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

31 March 2020

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression

31 March 2020

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

31 March 2020

1 reference

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

31 March 2020

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

31 March 2020

1 reference

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

31 March 2020

1 reference

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

31 March 2020

1 reference

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

31 March 2020

1 reference

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

31 March 2020

1 reference

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression

31 March 2020

1 reference

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

31 March 2020

1 reference

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response

31 March 2020

1 reference

Cetuximab: from bench to bedside.

31 March 2020

1 reference

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

31 March 2020

1 reference

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

31 March 2020

1 reference

Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor

31 March 2020

1 reference

Targeting epidermal growth factor receptor: central signaling kinase in lung cancer

31 March 2020

1 reference

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

31 March 2020

1 reference

4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors

31 March 2020

1 reference

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

31 March 2020

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

31 March 2020

1 reference

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

31 March 2020

1 reference

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.

31 March 2020

1 reference

The nuclear epidermal growth factor receptor signaling network and its role in cancer

31 March 2020

1 reference

12 December 2020

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

1 reference

12 December 2020

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner

1 reference

12 December 2020

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3559

1 reference

PubMed ID

23949426

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23949426